中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 556-561

Clinical efficacy of double plasma molecular absorption system and sequential plasma exchange combined with continuous renal replacement therapy in treatment of acute-on-chronic liver failure with acute kidney injury

DOI: 10.12449/JCH240319

  • Department of Infectious Diseases，The Affiliated Hospital of Guizhou Medical University，Guizhou 550002，China

Research funding:

Beijing Liver and Gall Blessing Foundation Artificial Liver Special Fund Project (RGGJJ-2021-001);

Fundamental Research Project of Guizhou Provincial Science and Technology Department（Qiankehe Foundation-ZK［2022］ General 452） 

More Information
  • Corresponding author: ZHU Juanjuan， 184184239@qq.com （ORCID： 0000-0003-0692-9200）
  • Received Date: 2023-06-10
  • Accepted Date: 2023-07-24
  • Published Date: 2024-03-20
    Abstract
  •   Objective  To investigate the clinical efficacy of double plasma molecular adsorption system （DPMAS） and sequential plasma exchange （PE） combined with continuous renal replacement therapy （CRRT） in the treatment of patients with acute-on-chronic liver failure （ACLF） and acute kidney injury （AKI）.  Methods  A retrospective analysis was performed for the clinical data of 90 patients with ACLF and AKI who were hospitalized in The Affiliated Hospital of Guizhou Medical University from January 2019 to December 2022， and according to the method for blood purification， they were divided into DPMAS sequential PE+CRRT group （observation group with 31 patients） and DPMAS sequential PE group （control group with 59 patients）. General data on admission and laboratory markers before and after blood purification were collected from all patients， including hepatic and renal function， coagulation function， and inflammation markers， and estimated glomerular filtration rate （eGFR） and MELD combined with serum sodium concentration （MELD-Na） score were calculated. The independent-samples t test was used for comparison of normally distributed continuous data between two groups； the Wilcoxon rank sum test was used for comparison of non-normally distributed continuous data within each group before and after treatment， and the Mann-Whitney U test was used for comparison between two groups； the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups.  Results  The observation group had a significantly higher response rate than the control group ［48.4% （15/31） vs 27.1% （16/59）， χ2=4.071， P=0.044］. The methods for blood purification in both groups could effectively improve total bilirubin， alanine aminotransferase， aspartate aminotransferase （AST）， prothrombin time activity， serum creatinine （Scr）， procalcitonin （PCT）， C-reactive protein， eGFR， and MELD-Na score （all P<0.05）， and both groups had significant reductions in platelet count （PLT） and hemoglobin （Hb） after treatment （all P<0.05）， while there were no significant changes in blood urea nitrogen， albumin， and international normalized ratio after treatment （all P>0.05）. There were significant differences between the two groups in the changes in AST， Scr， PCT， eGFR， MELD-Na score， Hb， and PLT after treatment （all P<0.05）.  Conclusion  DPMAS sequential PE combined with CRRT can effectively remove inflammatory mediators， improve renal function， stabilize the internal environment of human body， and achieve a relatively good clinical efficacy.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    MEZZANO G, JUANOLA A, CARDENAS A, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis[J]. Gut, 2022, 71( 1): 148- 155. DOI: 10.1136/gutjnl-2020-322161.
    [2]
    ALLEGRETTI AS. Acute kidney injury treatment in decompensated cirrhosis: a focus on kidney replacement therapy[J]. Kidney Med, 2021, 3( 1): 12- 14. DOI: 10.1016/j.xkme.2020.09.015.
    [3]
    XU W, LI Y, WANG L, et al. Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial[J]. BMJ Open, 2021, 11( 12): e047690. DOI: 10.1136/bmjopen-2020-047690.
    [4]
    Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification(2022 edition)[J]. J Clin Hepatol, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.

    中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.
    [5]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [6]
    ANGELI P, GINÈS P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. J Hepatol, 2015, 62( 4): 968- 974. DOI: 10.1016/j.jhep.2014.12.029.
    [7]
    ZACCHERINI G, WEISS E, MOREAU R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment[J]. JHEP Rep, 2020, 3( 1): 100176. DOI: 10.1016/j.jhepr.2020.100176.
    [8]
    BAI W, YAO C, MAO D, et al. The clinical efficacy of double plasma molecular absorption system combined with plasma exchange in the treatment of acute-on-chronic liver failure: a systematic review and meta-analysis[J]. J Healthc Eng, 2022, 2022: 3139929. DOI: 10.1155/2022/3139929
    [9]
    ZHANG YC, MA XX. Application of heterogeneous blood purification technology in the treatment of critically ill patients[J]. Chin J Nephrol Dialysis Transplantation, 2022, 31( 5): 442- 443. DOI: 10.3969/j.issn.1006-298X.2022.05.009.

    张育才, 马晓璇. 杂合式血液净化技术在危重症患者救治中的应用[J]. 肾脏病与透析肾移植杂志, 2022, 31( 5): 442- 443. DOI: 10.3969/j.issn.1006-298X.2022.05.009.
    [10]
    YAO YH, GAN JH, ZHAO WF. Effect of plasma exchange combined with continuous renal replacement therapy on the prognosis of patients with HBV-related acute-on-chronic liver failure and acute kidney injury[J]. J Clin Hepatol, 2019, 35( 5): 1065- 1069. DOI: 10.3969/j.issn.1001-5256.2019.05.026.

    姚运海, 甘建和, 赵卫峰. 血浆置换联合持续性肾脏替代治疗对HBV相关慢加急性肝衰竭合并急性肾损伤患者预后的影响[J]. 临床肝胆病杂志, 2019, 35( 5): 1065- 1069. DOI: 10.3969/j.issn.1001-5256.2019.05.026.
    [11]
    WU C, PENG W, CHENG D, et al. Efficacy and economic evaluation of nonbiological artificial liver therapy in acute-on-chronic hepatitis B liver failure[J]. J Clin Transl Hepatol, 2023, 11( 2): 433- 440. DOI: 10.14218/JCTH.2022.00106
    [12]
    LU J, LI DC, LIU Y, et al. Clinical efficacy of low-dose plasma exchange combined with double plasma molecular absorption system/hemoper-fusion in treatment of acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 11): 2526- 2531. DOI: 10.3969/j.issn.1001-5256.2022.11.017.

    鲁杰, 李顶春, 刘叶, 等. 小剂量血浆置换联合双重血浆分子吸附系统/血液灌流治疗慢加急性肝衰竭的效果分析[J]. 临床肝胆病杂志, 2022, 38( 11): 2526- 2531. DOI: 10.3969/j.issn.1001-5256.2022.11.017.
    [13]
    PORTE RJ, LISMAN T, TRIPODI A, et al. The International Normalized Ratio(INR) in the MELD score: problems and solutions[J]. Am J Transplant, 2010, 10( 6): 1349- 1353. DOI: 10.1111/j.1600-6143.2010.03064.x.
    [14]
    TAO Z, CHEN T, PAN Z, et al. Effect of high dose tigecycline on coagulation function in critically ill patients infected with multidrug-resistant bacteria[J]. Chin J Health Lab Technol, 2023, 33( 7): 831- 833.

    陶真, 陈通, 潘珍, 等. 高剂量替加环素对多重耐药菌感染危重患者凝血功能的影响[J]. 中国卫生检验杂志, 2023, 33( 7): 831- 833.
    [15]
    GUAN WT, KANG FX, LINW, et al. Decreased 90-day mortality in patients with hepatitis B-induced acute-on-chronic liver failure and acute kidney injury by continuous renal replacement therapy and plasma exchange treatment[J]. J Prac Hepatol, 2020, 23( 6): 833- 836. DOI: 10.3969/j.issn.1672-5069.2020.06.019.

    关万涛, 康福新, 林维, 等. CRRT联合PE治疗慢加急性乙型肝炎肝衰竭并发急性肾损伤患者疗效研究[J]. 实用肝脏病杂志, 2020, 23( 6): 833- 836. DOI: 10.3969/j.issn.1672-5069.2020.06.019.
    [16]
    WANG L, XU WX, ZHU Z, et al. Influence of artificial liver support system therapy on platelet in treatment of hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 5): 1053- 1058. DOI: 10.3969/j.issn.1001-5256.2022.05.015.

    王璐, 许文雄, 朱姝, 等. 人工肝治疗HBV相关慢加急性肝衰竭的血小板计数变化及其影响因素[J]. 临床肝胆病杂志, 2022, 38( 5): 1053- 1058. DOI: 10.3969/j.issn.1001-5256.2022.05.015.
    [17]
    JIA JF, LIANG F, HUANG JW, et al. Effect of artificial liver with double plasma molecular absorb system model on patients’platelets and corresponding treatment strategy[J]. J Peking Univ: Health Sci, 2022, 54( 3): 548- 551. DOI: 10.19723/j.issn.1671-167X.2022.03.

    贾金凤, 梁菲, 黄建伟, 等. 双重血浆分子吸附系统模式人工肝治疗对血小板的影响[J]. 北京大学学报(医学版), 2022, 54( 3): 548- 551. DOI: 10.19723/j.issn.1671-167X.2022.03.
    [18]
    ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74( 3): 670- 685. DOI: 10.1016/j.jhep.2020.11.048.
    [19]
    BORGONOVO A, BALDIN C, MAGGI DC, et al. Systemic inflammatory response syndrome in patients hospitalized for acute decompensation of cirrhosis[J]. Can J Gastroenterol Hepatol, 2021, 2021: 5581587. DOI: 10.1155/2021/5581587
    [20]
    ZHENG W, LIANG X, SHUI L, et al. Serum procalcitonin correlates with renal function in hepatitis b virus-related acute-on-chronic liver failure[J]. Cell Physiol Biochem, 2018, 50( 5): 1794- 1803. DOI: 10.1159/000494820.
    [21]
    KAN WC, HUANG YT, WU VC, et al. Predictive ability of procalcitonin for acute kidney injury: a narrative review focusing on the interference of infection[J]. Int J Mol Sci, 2021, 22( 13): 6903. DOI: 10.3390/ijms22136903.
    [22]
    LIU J, LI H, XIA J, et al. Baseline neutrophil-to-lymphocyte ratio is independently associated with 90-day transplant-free mortality in patients with cirrhosis[J]. Front Med(Lausanne), 2021, 8: 726950. DOI: 10.3389/fmed.2021.726950.
    [23]
    SUN J, GUO H, YU X, et al. A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2021, 21( 1): 422. DOI: 10.1186/s12876-021-02007-w.
    [24]
    WEI W, HUANG X, YANG L, et al. Neutrophil-to-Lymphocyte ratio as a prognostic marker of mortality and disease severity in septic Acute kidney injury Patients: A retrospective study[J]. Int Immunopharmacol, 2023, 116: 109778. DOI: 10.1016/j.intimp.2023.109778.
    [25]
    WU ZB, ZHENG YB, WANG K, et al. Plasma interleukin-6 level: A potential prognostic indicator of emergent HBV-associated ACLF[J]. Can J Gastroenterol Hepatol, 2021, 2021: 5545181. DOI: 10.1155/2021/5545181.
    [26]
    NAPOLEONE L, SOLÉ C, JUANOLA A, et al. Patterns of kidney dysfunction in acute-on-chronic liver failure: Relationship with kidney and patients’ outcome[J]. Hepatol Commun, 2022, 6( 8): 2121- 2131. DOI: 10.1002/hep4.1963.
    [27]
    NAND N, VERMA P, JAIN D. Comparative evaluation of continuous veno-venous hemodiafiltration and continuous arterio-venous hemodiafiltration in patients of hepatic failure and/or hepatorenal syndrome[J]. J Assoc Physicians India, 2019, 67( 8): 39- 42.
    [28]
    ZHANG J, TIAN J, SUN H, et al. How does continuous renal replacement therapy affect septic acute kidney injury?[J]. Blood Purif, 2018, 46( 4): 326- 331. DOI: 10.1159/000492026.
    [29]
    SARAIVA IE, ORTIZ-SORIANO VM, MEI X, et al. Continuous renal replacement therapy in critically ill patients with acute on chronic liver failure and acute kidney injury: A retrospective cohort study[J]. Clin Nephrol, 2020, 93( 4): 187- 194. DOI: 10.5414/CN109983.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (380) PDF downloads(58) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return